COMP <GO>
EWTX vs UNH // 10Y YIELD & FRED MACRO BETA
Edgewise Therapeutics Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: EWTX 2
— UNH 10
▲ 10Y YIELD & FRED MACRO BETA LEADER: EWTX
LAST: $38.91 (-3.90%) • MKT CAP: $4.23B
macro-sensitivity
1.10
LAST: $410.91 (+0.94%) • MKT CAP: $368.83B
macro-sensitivity
0.33
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EWTX VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EWTX | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 88.57% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -31.90% | 11.47% | -43.37 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 16.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.41% | 6.48% | -9.89 | UNH | /fcf-yield <GO> |
| Operating Margin | -16.20% | 4.82% | -21.02 | UNH | /operating-margins <GO> |
| Net Profit Margin | 0.00% | 3.14% | -3.14 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | -1.10% | 6.46% | -7.56 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 3.12 | +22.88 | EWTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 7/9 | -4.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.8 | 59.2 | -13.40 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 1.10 | 0.33 | +0.77 | EWTX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 25.0x | 17.1x | +7.91 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.23B | $368.83B | -$364.60B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EWTX REV | UNH REV | EWTX GROSS % | UNH GROSS % | EWTX FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $447.57B | — | 88.7% | -$144.1M | $16.07B |
| FY 2024 | $0 | $400.28B | — | 88.3% | -$110.3M | $20.70B |
| FY 2023 | $0 | $371.62B | — | 89.6% | -$91.9M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EWTX // BETA 1.10
UNH // BETA 0.33